These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23379595)

  • 1. Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met.
    Northrup AB; Katcher MH; Altman MD; Chenard M; Daniels MH; Deshmukh SV; Falcone D; Guerin DJ; Hatch H; Li C; Lu W; Lutterbach B; Allison TJ; Patel SB; Reilly JF; Reutershan M; Rickert KW; Rosenstein C; Soisson SM; Szewczak AA; Walker D; Wilson K; Young JR; Pan BS; Dinsmore CJ
    J Med Chem; 2013 Mar; 56(6):2294-310. PubMed ID: 23379595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.
    Katz JD; Jewell JP; Guerin DJ; Lim J; Dinsmore CJ; Deshmukh SV; Pan BS; Marshall CG; Lu W; Altman MD; Dahlberg WK; Davis L; Falcone D; Gabarda AE; Hang G; Hatch H; Holmes R; Kunii K; Lumb KJ; Lutterbach B; Mathvink R; Nazef N; Patel SB; Qu X; Reilly JF; Rickert KW; Rosenstein C; Soisson SM; Spencer KB; Szewczak AA; Walker D; Wang W; Young J; Zeng Q
    J Med Chem; 2011 Jun; 54(12):4092-108. PubMed ID: 21608528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
    J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
    Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
    Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.
    Raeppel S; Gaudette F; Mannion M; Claridge S; Saavedra O; Isakovic L; Déziel R; Beaulieu N; Beaulieu C; Dupont I; Nguyen H; Wang J; Macleod AR; Maroun C; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2010 May; 20(9):2745-9. PubMed ID: 20363625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
    Dussault I; Bellon SF
    Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Raeppel S; Claridge S; Saavedra O; Gaudette F; Zhan L; Mannion M; Zhou N; Raeppel F; Granger MC; Isakovic L; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman J; Vaisburg A
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1323-8. PubMed ID: 19211249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461.
    Wu JF; Liu MM; Huang SX; Wang Y
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3251-5. PubMed ID: 26077488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors.
    Raeppel SL; Therrien E; Raeppel F
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
    Boezio AA; Copeland KW; Rex K; K Albrecht B; Bauer D; Bellon SF; Boezio C; Broome MA; Choquette D; Coxon A; Dussault I; Hirai S; Lewis R; Lin MH; Lohman J; Liu J; Peterson EA; Potashman M; Shimanovich R; Teffera Y; Whittington DA; Vaida KR; Harmange JC
    J Med Chem; 2016 Mar; 59(6):2328-42. PubMed ID: 26812066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.
    Raeppel SL; Raeppel F; Therrien E
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
    Zhang D; Ai J; Liang Z; Zhu W; Peng X; Chen X; Ji Y; Jiang H; Luo C; Geng M; Liu H
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2408-13. PubMed ID: 23474386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
    Zhang J; Lv X; Ma X; Hu Y
    Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
    Zhan Z; Peng X; Liu Q; Chen F; Ji Y; Yao S; Xi Y; Lin Y; Chen T; Xu Y; Ai J; Geng M; Duan W
    Eur J Med Chem; 2016 Jun; 116():239-251. PubMed ID: 27061987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.